Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus

INTRODUCTION: Linagliptin is a xanthine-based dipeptidyl peptidase (DPP)-4 inhibitor that is now available in numerous countries worldwide for the treatment of type 2 diabetes mellitus (T2DM). The aim of this study was to evaluate further the mechanisms underlying the improvements in glycemic contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Rauch, Thomas, Graefe-Mody, Ulrike, Deacon, Carolyn F., Ring, Arne, Holst, Jens J., Woerle, Hans-Juergen, Dugi, Klaus A., Heise, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare Communications 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508116/
https://www.ncbi.nlm.nih.gov/pubmed/22986920
http://dx.doi.org/10.1007/s13300-012-0010-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508116/
https://www.ncbi.nlm.nih.gov/pubmed/22986920
http://dx.doi.org/10.1007/s13300-012-0010-y

Ejemplares similares